Labcorp Publishes 2023 Corporate Responsibility Report

Highlights include progress on initiatives aimed at protecting the environment, cultivating a skilled and diverse workforce and expanding health access to underserved communities

Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit

The first at-home mpox testing kit provides patients with convenience and privacy to test for mpox, supports physicians in detection and treatment BURLINGTON, N.C. , April 10, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Portfolio expansion solidifies company's commitment to advancing cancer research and patient care BURLINGTON, N.C. , April 8, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision

New Vivarium Wing in Münster

Immuno-oncology. Biologics. Cell and gene therapies. This is the future of medicine. It’s more personalized, more complex and driving an increase in demand for highly technical nonclinical studies that require study models that most closely resemble the human body. Oftentimes, it’s nascent science that demands a new study that hasn’t even been invented yet.

Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research

Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer BURLINGTON, N.C. , April 5, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of